Brought to you by 
Investor group plans to take Chinese pharmaco Simcere private; finalized at $122mm.
19 Feb 2014
Executive Summary
Simcere Pharmaceutical Group’s founder and chairman Jinsheng Ren, plus a company he controls, New Good Management, along with Assure Ahead Investments (owned by Hony Capital) and its affiliates have sent Simcere a nonbinding proposal to acquire approximately 44.6% of the shares of the public Chinese pharmaco that they don’t already hold for $238mm, or $9.56 per ADS (a 20% premium). Simcere has put together a special committee to evaluate the offer.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Vaccines
Deal Status
- Final
Deal Type
-
Acquisition
- Buy-out
- Includes Contract
- Partial Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Investor group plans to take Chinese pharmaco Simcere private; finalized at $122mm.
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice